TXG Stock Climbs As Legal Win And AI Deal Shape Outlook

10x Genomics Inc. stocks have been trading up by 7.52 percent after upbeat coverage of its advancing single-cell sequencing platform.

Live Update At 12:32:44 EDT: On Thursday, September 24, 2026 10x Genomics Inc. stock [NASDAQ: TXG] is trending up by 7.52%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TXG has been on a strong short-term run. From 2026/08/31 to 2026/09/24, 10x Genomics stock climbed from about $62.45 to $81.28, a move of roughly 30%. That’s a serious trend, not just noise. The daily chart shows a steady stair-step higher with brief pullbacks, classic momentum behavior that active traders look for.

Intraday on 2026/09/24, TXG opened at $75.50, dipped to $74.60, then pushed to $82.09 before settling just above $81. That shows dip-buying strength and aggressive demand into highs. The 5‑minute tape is full of higher lows and controlled pullbacks, not wild reversals.

Fundamentally, TXG is still a growth story with red ink. Quarterly revenue sits around $151.0M, with gross margin near 70%, but operating loss was about $22.96M and net loss roughly $17.93M. Key profitability ratios are negative, with return on equity and assets both below zero. Yet 10x Genomics carries over $502.5M in cash, low debt, and a current ratio around 5.7, so liquidity is not the problem. For traders, TXG is a classic high-valuation, high-expectation name: pricey on sales and cash flow, but backed by strong balance sheet and sector growth.

Why Traders Are Watching TXG Right Now

TXG is drawing serious attention because the story mixes hard catalysts with a powerful chart. On the legal front, 10x Genomics just scored a Delaware jury win over Qiagen’s Parse Biosciences unit. The jury confirmed three Scale Biosciences single‑cell patents as valid and infringed, tied to the Evercode Whole Transcriptome product. Damages came in at about $4.8M, based on a 14% royalty from 2021 to mid‑2026, and TXG plans to chase enhanced damages, attorneys’ fees, and a possible U.S. injunction.

For a company with a multi‑$B enterprise value, $4.8M is not the story. The signal is that TXG’s intellectual property in single-cell analysis holds up in court. That strengthens 10x Genomics’ moat and can pressure a rival’s U.S. offerings. Yet, even after this win, TXG stock traded down roughly 5% in a weak healthcare/biotech tape, reminding traders that macro flows still matter.

On the innovation side, TXG is partnering with Korea-based Lunit to bolt AI pathology (Lunit SCOPE IO) onto its Xenium and Atera spatial platforms. The combo of H&E image analysis with spatial molecular data aims to sharpen tumor characterization and biomarker discovery, especially for antibody‑drug conjugates and immunotherapy response prediction. This is long-tail stuff, but it signals that 10x Genomics is leaning into oncology and spatial biology where it already holds more than 60% share in spatial profiling.

Wall Street is noticing. RBC launched coverage on TXG at Sector Perform with a $70 target, highlighting double‑digit growth and leadership in spatial profiling but flagging roughly flat single‑cell revenue for the next five years. UBS came in Neutral at $68, and Deutsche Bank hiked its target from $40 to $70 while keeping a Hold on TXG. Across the board, TXG still carries an average Overweight rating and a consensus target around $52.13, showing the Street likes the long-term story but is respectful of valuation and segment maturity.

Layer on insider activity: CFO Adam Taich sold about 46,388 shares (~$3.0M) and director John R. Stuelpnagel sold 20,000 shares (~$1.24M). Both still hold north of 300,000 Class A shares each, so they remain heavily exposed, but multiple sales naturally make shorter‑term traders a bit more cautious at elevated prices.

Conclusion

TXG sits at a pivotal spot where price momentum, legal wins, and tech partnerships all collide. The stock has ripped from the low‑$60s to above $80 while 10x Genomics is still posting quarterly losses and trading at rich price‑to‑sales and cash‑flow multiples. The Delaware patent verdict reinforces the company’s single‑cell IP, and the Lunit AI pathology partnership deepens its edge in spatial and oncology workflows. At the same time, the Street is openly questioning how long TXG’s core single-cell franchise can grow, even as it cheers the spatial biology runway.

For active traders, this is a classic battleground between lofty expectations and real execution. TXG’s strong cash position, minimal leverage, and >60% spatial share provide a solid base. But the mixed analyst ratings, cautious outlook on single‑cell, and recent insider sales tell you not everyone is chasing at these levels. TXG will likely remain highly reactive to news on Atera adoption, spatial growth, and any next steps in the Parse litigation, especially if an injunction or enhanced damages come through.

As Tim Sykes loves to remind traders, “patterns repeat, but they don’t always complete.” As millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.”. TXG’s recent breakout fits the momentum pattern, but the only way to manage a name like this is with strict rules. Use the news, respect the trend, and, above all, cut losses fast.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks